Microbot Medical Inc. (NASDAQ:MBOT) is at $1.38 seeing a daily low of $1.28 and high of $1.42. The big move identifies the stock as one of the most volatile of the day.
It is among the market’s biggest gainers today. Shares last traded at $1.38 which is quite a bit higher than the 50 day moving average of $1.10 and which is significantly lower than the 200 day moving average of $3.03. The 50 day moving average went up by +25.0657% whereas the 200 day average was down by -54.5014%.
Investors are a little more bearish on Microbot Medical Inc. lately if you pay attention to the motion in short interest. The company had a rise in short interest of 8.79% between August 15, 2017 and August 31, 2017. Short shares increased 183,357 over that period. The days to cover increased to 4.0 and the percentage of shorted shares is 0.16% as of August 31.
Here is a rundown on some insider market activity for Microbot Medical Inc. (NASDAQ:MBOT). Director Yoseph Bornstein disclosed the sale of 45,610 shares of MBOT stock. The shares were sold on September 6th for an average price of $1.03. Bornstein now owns $5,381,543 of the stock per the Form 4 SEC filing. Yoseph Bornstein, Director disclosed the sale of 10,000 shares of (MBOT). The shares were purchased at an average price of $1.07. The Director now owns $5,639,338 of the stock according to the SEC filing.
Yoseph Bornstein, Director disclosed the sale of 25,000 shares. The shares sold for $1.06. The Director now owns $5,597,234 of the stock per the Form 4 SEC filing.
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and related technologies. It develops HuCNS-SC platform technology, a purified human neural stem cells used as a potential therapeutic to treat diseases and disorders of the central nervous system. The company’s HuCNS-SC is in Phase I clinical trials for the treatment of Pelizeaus-Merzbacher Disease; and has completed a Phase I clinical trial for infantile and late infantile neuronal ceroid lipofuscinosis. Its HuCNS-SC is also in Phase I/II clinical trials for the treatment of thoracic spinal cord injury; Phase II clinical trials for the treatment of cervical spinal cord injury; and Phase I/II clinical trials for dry age-related macular degeneration. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California..